Reuters -- A single study looking at a proposed new use for Salix Pharmaceuticals’ (SLXP.O) Xifaxan to treat a liver disorder looks promising, but the results are hard to interpret and possible side effects are a concern, U.S. health regulatory staff said in documents released on Friday.
